Samarth Kulkarni
Chief Executive Officer at CRISPR Therapeutics AG
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: CRISPR Therapeutics AG, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
CRISPR Therapeutics AG June 4, 202696.7%
-
Black Diamond Therapeutics Inc. June 12, 202541.2%
-
CRISPR Therapeutics AG June 5, 202598.1%
-
CRISPR Therapeutics AG May 30, 202498.8%
-
CRISPR Therapeutics AG June 8, 202397.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 19, 2026 | CRISPR Therapeutics AG | Open-market sale | −47,837 | $49.78 | $2,381,326 |
| Oct 16, 2026 | CRISPR Therapeutics AG | Option exercise | +100,000 | — | — |
| Mar 23, 2026 | CRISPR Therapeutics AG | Open-market sale | −10,020 | $46.78 | $468,736 |
| Mar 20, 2026 | CRISPR Therapeutics AG | Option exercise | +19,687 | — | — |
| Mar 16, 2026 | CRISPR Therapeutics AG | Open-market sale | −10,349 | $48.26 | $499,443 |
| Mar 14, 2026 | CRISPR Therapeutics AG | Option exercise | +20,625 | — | — |
| Mar 11, 2026 | CRISPR Therapeutics AG | Open-market sale | −9,798 | $52.80 | $517,334 |
| Mar 10, 2026 | CRISPR Therapeutics AG | Option exercise | +19,250 | — | — |
| Feb 19, 2026 | CRISPR Therapeutics AG | Open-market sale | −6,967 | $52.58 | $366,325 |
| Feb 18, 2026 | CRISPR Therapeutics AG | Option exercise | +13,250 | — | — |
| Jan 22, 2026 | CRISPR Therapeutics AG | Open-market sale | −60,000 | $60.23 | $3,613,800 |
| Jan 20, 2026 | CRISPR Therapeutics AG | Open-market sale | −21,433 | $51.61 | $1,106,157 |
| Jan 20, 2026 | CRISPR Therapeutics AG | Open-market sale | −8,567 | $52.10 | $446,341 |
| Dec 18, 2025 | CRISPR Therapeutics AG | Gift | −30,000 | — | — |
| Oct 17, 2025 | CRISPR Therapeutics AG | Open-market sale | −50,895 | $67.91 | $3,456,279 |
Questions about Samarth Kulkarni
What boards is Samarth Kulkarni on?
Samarth Kulkarni sits on the boards of Black Diamond Therapeutics Inc., CRISPR Therapeutics AG and Oruka Therapeutics Inc.
What company is Samarth Kulkarni the CEO of?
Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG.
How long has Samarth Kulkarni served on boards?
Our records show at least 10 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.